Drugs / Amlodipine
Amlodipine
also known as
amlodipine besylate · Norvasc · AML · amlodipine besilate · HGP0904 · amlodipine camsylate · ALD · Amlo · +11 more
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Dafiro | — | 2007-01-15 | europa.eu ↗ |
| Label expansions (4) | US (FDA) | NORVASC | — | 1996-06-14 – 2005-09-28 | fda.gov ↗ |
| Approved | US (FDA) | NORVASC | — | 1992-07-31 | fda.gov ↗ |
Trials 352 · started per year
today
US approved 1992
EU approved 2007
1
1
1
1
1
1
4
1
10
20
13
22
25
25
14
18
14
9
13
26
17
16
13
13
11
10
10
17
4
8
6
5
198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07291375 | Dec 2025 → Jun 2026 overdue | — | Minia University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT02744456 | Aug 2014 → Aug 2017 | hypertensive disorder | Columbia University | Completed | No outcome recorded |
| Phase 185 trials | ||||||
| Phase 1 | NCT07075965 | Dec 2026 → Oct 2030 expected | myotonic dystrophy type 1 | University of Rochester | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06012487 | May → Dec 2026 expected | — | Cedars-Sinai Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05808725 | Dec 2022 → Apr 2023 | coronary artery disorder, hypertensive disorder | Brillian Pharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05688085 | Oct → Dec 2022 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05688098 | Sep → Nov 2022 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05663073 | Sep → Dec 2022 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05259020 | Feb → Mar 2022 | hyperlipidemia, hypertensive disorder | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05077475 | Sep 2021 → Apr 2022 | hypertensive disorder | AJU Pharm Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05077462 | Sep 2021 → Apr 2022 | hypertensive disorder | AJU Pharm Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04611932 | Nov 2020 → Mar 2021 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04627207 | Nov 2020 → Mar 2021 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04185090 | Feb → Apr 2020 | hyperlipidemia, hypertensive disorder | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT04262765 | Feb → Mar 2019 | — | Midas Pharma GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04245046 | Jan → Feb 2019 | — | Midas Pharma GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04322266 | Dec 2018 → Feb 2019 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03707899 | Dec 2018 → Feb 2019 | hyperlipidemia, combined, 2 | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03662620 | Oct → Dec 2018 | hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03629067 | Sep → Nov 2018 | — | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03657550 | May → Sep 2018 | hypertensive disorder | Conjupro Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04081844 | May → Jun 2018 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03247140 | Jun → Aug 2017 | hyperlipidemia, combined, 2 | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03461081 | May → Jul 2017 | hyperlipidemia, combined, 2 | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03116516 | Apr → May 2017 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03032315 | Oct → Dec 2016 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02920047 | Oct 2016 → Jan 2017 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02995720 | Aug → Nov 2016 | hyperlipidemia | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02951962 | Aug → Sep 2016 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02814500 | Jul → Sep 2016 | — | Alvogen Korea | Unknown | No outcome recorded |
| Phase 1 | NCT02789475 | May → Jul 2016 | hyperlipidemia, hypertensive disorder | Alvogen Korea | Unknown | No outcome recorded |
| Phase 1 | NCT02739672 | Jan → Apr 2016 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02665832 | Jan → Jun 2016 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT02933658 | Nov 2015 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02569814 | Sep → Dec 2015 | hyperlipidemia, hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02548286 | Aug 2015 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02397538 | Feb → Apr 2015 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02243319 | Sep → Dec 2014 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02387554 | Aug → Oct 2014 | hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT02205151 | Jul → Sep 2014 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02233218 | Jul → Oct 2014 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02064621 | Jun → Aug 2014 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02152969 | May → Aug 2014 | hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02064556 | May → Jul 2014 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02955498 | Apr → May 2014 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02075619 | Mar → Jul 2014 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02069821 | Mar 2014 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02060019 | Mar → Jun 2014 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03889145 | Dec 2013 → Feb 2014 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02058472 | Dec 2013 → May 2014 | — | Dong-A Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01926652 | Jul → Aug 2013 | — | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01822639 | Apr → May 2013 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01845272 | Apr → Jul 2013 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT01841593 | Apr → Sep 2013 | HIV infectious disease | St Stephens Aids Trust | Completed | No outcome recorded |
| Phase 1 | NCT01735890 | Sep → Nov 2012 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01648231 | Aug → Sep 2012 | hypertensive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01776047 | Jul → Sep 2012 | — | Dong-A Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01823913 | Jul → Aug 2012 | — | Severance Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01549496 | May → Sep 2012 | hepatitis C virus infection, hypertensive disorder | Ottawa Hospital Research Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT02295046 | Oct 2011 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02292069 | Sep 2011 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02962258 | May → Jun 2011 | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT01341392 | Apr → Aug 2011 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01198249 | Sep 2010 → Feb 2011 | essential hypertension | Yonsei University | Completed | No outcome recorded |
| Phase 1 | NCT01181011 | Aug → Nov 2010 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01138826 | May → Jun 2010 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01130168 | May → Nov 2010 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01117038 | Apr → May 2010 | erectile dysfunction | VIVUS LLC | Completed | No outcome recorded |
| Phase 1 | NCT02261064 | Dec 2008 → Feb 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00789321 | Jul 2008 → Feb 2009 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03912285 | Jan 2008 → Mar 2009 | — | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02259803 | Oct → Nov 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259777 | Sep → Nov 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259790 | Jul → Aug 2007 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02194309 | Sep → Dec 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02259816 | May → Aug 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00870142 | Apr → May 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00870571 | Apr → May 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00649519 | May 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649402 | May → Jun 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00834977 | Apr → May 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00835367 | Mar 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00841815 | Apr → May 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00841542 | Apr → May 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00039975 | ? → Apr 2004 | HIV infectious disease, hypertensive disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00932763 | — | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT00932880 | — | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00156403 | Aug → Dec 2005 | pancreatitis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 220 trials | ||||||
| Phase 2 | NCT06942377 | Jul 2025 → Jan 2027 expected | endometrial carcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05331144 | Oct 2022 → Jun 2027 expected | hereditary dementia, hypertensive disorder, subjective cognitive decline | Rong Zhang | Recruiting | No outcome recorded |
| Phase 2 | NCT05370599 | Apr 2022 → Jan 2026 | hypertensive disorder | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 2 | NCT06212648 | Mar → Nov 2022 | essential hypertension | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04954196 | Oct 2021 → Oct 2023 | — | University Hospital, Montpellier | Withdrawn | No outcome recorded |
| Phase 2 | NCT04692467 | Feb 2021 → Jun 2023 | HIV infectious disease | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT04179019 | Sep 2020 → Dec 2023 | primary aldosteronism | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04488978 | May 2020 → Nov 2021 | essential hypertension | Handok Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03640312 | Aug 2019 → May 2022 | hypertensive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03024476 | Sep 2016 → Dec 2017 | hypertensive disorder, ischemic stroke | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02278471 | Dec 2015 → Jun 2018 | hyperlipidemia, hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT02944734 | Sep 2014 → Dec 2015 | essential hypertension | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02206165 | Mar 2014 → Apr 2015 | essential hypertension | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 2 | NCT02059616 | Feb 2014 → Jun 2015 | essential hypertension | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT01518998 | Aug 2011 → Oct 2013 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01264692 | Feb 2011 → Jan 2012 | essential hypertension | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00942344 | May → Dec 2007 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 2 | NCT00015457 | Apr 2001 → Apr 2009 | focal dystonia | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00151619 | Feb 1999 → Sep 2001 | heart failure | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00000522 | Aug 1985 → May 1994 | heart disorder, hypertensive disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 2/311 trials | ||||||
| Phase 2/3 | NCT06424834 | Oct 2024 → Dec 2026 expected | coronary artery intramyocardial course, coronary microvascular disorder, coronary vasospasm, intermediate coronary syndrome | Stanford University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02913664 | Feb 2017 → Nov 2021 | hypertensive disorder, subjective cognitive decline | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT02065492 | Feb 2014 → Oct 2015 | thalassemia | Aga Khan University | Completed | No outcome recorded |
| Phase 2/3 | NCT02408172 | Oct 2013 → Jun 2017 | hypertensive disorder, obstructive sleep apnea syndrome | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01956786 | Sep → Dec 2013 | essential hypertension | Shenzhen Ausa Pharmed Co.,Ltd | Unknown | No outcome recorded |
| Phase 2/3 | NCT01848873 | Jan → Aug 2013 | essential hypertension | Shenzhen Ausa Pharmed Co.,Ltd | Unknown | No outcome recorded |
| Phase 2/3 | NCT01255475 | Jan 2011 → Oct 2012 | congestive heart failure | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2/3 | NCT01280266 | Jan → May 2011 | Raynaud disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT04740840 | May 2010 → Apr 2012 | hypertensive disorder | Affiliated Hospital of North Sichuan Medical College | Completed | No outcome recorded |
| Phase 2/3 | NCT01125254 | Sep 2008 → Jul 2011 | beta-thalassemia major | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 2/3 | NCT00425373 | Nov 2006 → Mar 2008 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3103 trials | ||||||
| Phase 3 | NCT07618806 | Nov 2026 → Dec 2027 expected | hypertensive disorder | Zentiva, k.s. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07704697 | Nov 2024 → Nov 2025 | essential hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06348576 | May 2024 → Feb 2025 | essential hypertension | Addpharma Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT06236061 | Apr 2024 → May 2025 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT06052748 | Feb 2024 → Mar 2025 | essential hypertension | Addpharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT07704684 | Jun 2023 → Aug 2025 | essential hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT07564726 | Aug 2022 → Feb 2024 | essential hypertension, hyperlipoproteinemia | Celltrion Pharm, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05475665 | Jul 2022 → Mar 2023 | essential hypertension | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05476354 | Jul 2022 → Apr 2023 | essential hypertension | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05155137 | Dec 2021 → Dec 2029 expected | cognitive disorder, stroke disorder | Hospital Moinhos de Vento | Recruiting | No outcome recorded |
| Phase 3 | NCT04518293 | Jul 2021 → Aug 2023 | hypertensive disorder | George Medicines PTY Limited | Completed | No outcome recorded |
| Phase 3 | NCT04518306 | Jun 2021 → Sep 2023 | hypertensive disorder | George Medicines PTY Limited | Completed | No outcome recorded |
| Phase 3 | NCT03785067 | Feb 2020 → Feb 2021 | hypertensive disorder, intracerebral hemorrhage, vascular dementia | The George Institute | Terminated | No outcome recorded |
| Phase 3 | NCT04161001 | Nov 2019 → Nov 2021 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 3 | NCT03991442 | Jun 2019 → Mar 2021 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05820880 | May 2019 → Feb 2022 | essential hypertension | Servier | Completed | No outcome recorded |
| Phase 3 | NCT02699645 | Sep 2017 → Aug 2025 | hypertensive disorder, intracerebral hemorrhage | The George Institute | Completed | No outcome recorded |
| Phase 3 | NCT03103256 | May 2017 → Apr 2018 | hyperlipidemia | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02969265 | May 2017 → Jul 2018 | hypertensive disorder | Takeda | Withdrawn | No outcome recorded |
| Phase 3 | NCT03067688 | Apr 2017 → Mar 2018 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03009487 | Jan 2017 → Apr 2018 | hyperlipidemia, hypertensive disorder | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT02979197 | Nov 2016 → Jul 2017 | hypertensive disorder | Kitov Pharma Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03210532 | Oct 2016 → Sep 2017 | hyperlipidemia, hypertensive disorder | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03088254 | Sep 2016 → Jul 2017 | — | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03566316 | Nov 2015 → Jun 2017 | hyperlipidemia, combined, 2 | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02651870 | Apr 2015 → Feb 2016 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT02368652 | Dec 2014 → Nov 2015 | essential hypertension | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02368665 | Dec 2014 → Nov 2015 | essential hypertension | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02277691 | Nov 2014 → Apr 2016 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT04952051 | Jul 2014 → Jul 2019 | hypertensive disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| Phase 3 | NCT02899455 | Jul 2014 → Jun 2016 | hyperlipidemia, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT02172040 | Jun 2014 → Nov 2015 | hypertensive disorder | Kitov Pharmaceuticals, Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02152306 | Apr 2014 → Mar 2015 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01865188 | Apr 2014 → Apr 2015 | essential hypertension | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01977794 | Mar 2014 → Mar 2015 | essential hypertension | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 3 | NCT01911780 | Jul 2013 → Jan 2015 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01838850 | Apr 2013 → Aug 2014 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT01395199 | Aug 2012 → Feb 2015 | beta-thalassemia major, disorder of iron metabolism and transport | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 3 | NCT01625494 | May 2012 → Jan 2013 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01557153 | Apr 2012 → Apr 2014 | depressive disorder | Gateshead Health NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 3 | NCT01613209 | Dec 2011 → Sep 2012 | hypertensive disorder | Institute for Pharmacology and Preventive Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01299376 | Jan → Nov 2011 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01259297 | Jan 2011 → Nov 2012 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01237873 | Jan 2011 → Feb 2012 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01204398 | Nov 2010 → Jul 2011 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01222520 | Oct 2010 → Jun 2011 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01113047 | May → Oct 2010 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01134393 | May 2010 → May 2011 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01001572 | Sep 2009 → May 2010 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00957554 | Jul 2009 → Sep 2010 | hypertensive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00956644 | Jul 2009 → Aug 2010 | essential hypertension | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00923091 | Jun 2009 → Jan 2011 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT01127217 | May 2009 → Mar 2010 | hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT00867490 | Mar → Aug 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00797862 | Nov 2008 → Nov 2010 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00778921 | Oct 2008 → Jun 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00777946 | Oct 2008 → May 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00765674 | Sep 2008 → Aug 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00739973 | Sep 2008 → May 2009 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00667719 | Jun 2008 → Oct 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00940667 | May → Dec 2008 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT00699192 | May 2008 → May 2009 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00649389 | May 2008 → Apr 2009 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00940680 | Apr → Nov 2008 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT00624052 | Mar 2008 → Jun 2009 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00614380 | Jan 2008 → Mar 2009 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00618774 | Jan 2008 → Oct 2009 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00553267 | Nov 2007 → Oct 2008 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00558428 | Oct 2007 → Sep 2008 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00550953 | Oct 2007 → Jul 2008 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00558064 | Oct 2007 → Sep 2008 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00527514 | Sep 2007 → Apr 2008 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00548067 | Sep 2007 → Mar 2008 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00523744 | Jul → Dec 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00443456 | May 2007 → Jun 2008 | hypertensive disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00446563 | Mar 2007 → Mar 2010 | hypertensive heart disease | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00446524 | Feb 2007 → Oct 2008 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00413413 | Jan → Nov 2007 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00437645 | Jan → Nov 2007 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00415623 | Jan → Oct 2007 | hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00402103 | Nov 2006 → Apr 2008 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00392262 | Aug 2006 → Feb 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00353912 | Jun 2006 → Apr 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00350168 | Jun 2006 → Apr 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00327587 | May 2006 → Aug 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00281580 | Apr 2006 → Mar 2007 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00327145 | Mar 2006 → Jan 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00289406 | Jan → Feb 2006 | hypertensive disorder | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00367939 | Dec 2005 → Jul 2006 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00185133 | May 2005 → Jan 2007 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00220220 | Apr 2005 → Apr 2007 | essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT00171002 | Nov 2004 → Jun 2005 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00170963 | Oct 2004 → Jun 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00171535 | Oct 2004 → Apr 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00330785 | Oct 2004 → Sep 2005 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00171366 | Jul 2004 → Jul 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00170976 | Apr 2004 → Jun 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00409643 | Jan → Jul 2004 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00170950 | Oct 2003 → Jan 2008 | hypertensive disorder | Novartis | Terminated | No outcome recorded |
| Phase 3 | NCT00409851 | Apr 2003 → Mar 2005 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00409760 | Jan 2003 → Feb 2004 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT04364139 | Feb 1995 → Sep 2001 | chronic kidney disease, nephrosclerosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00000542 | Aug 1993 → Mar 2002 | coronary artery disorder, diabetes mellitus, heart failure, hyperlipidemia +3 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 4110 trials | ||||||
| Phase 4 | NCT07240909 | Jan → Dec 2026 expected | hypertensive disorder | The Third Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06730945 | Jun 2025 → Dec 2028 | — | Ruijin Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT04974151 | Aug 2024 → Jun 2029 expected | hyperhomocysteinemia, hypertensive disorder | Shenzhen Ausa Pharmed Co.,Ltd | Recruiting | No outcome recorded |
| Phase 4 | NCT04974138 | Aug 2024 → Jun 2030 expected | hyperhomocysteinemia, hypertensive disorder | Shenzhen Ausa Pharmed Co.,Ltd | Recruiting | No outcome recorded |
| Phase 4 | NCT05917275 | Apr 2024 → Oct 2025 | essential hypertension | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT06275763 | Oct 2023 → Dec 2025 | hypertensive disorder | National Institute of Cardiology, Warsaw, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT06487949 | Dec 2022 → Oct 2023 | hypertensive disorder | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT05683301 | Aug 2022 → Aug 2024 | essential hypertension | Centre for Chronic Disease Control, India | Completed | No outcome recorded |
| Phase 4 | NCT05377203 | Jul 2022 → Jul 2023 | hypertensive disorder | The Third Xiangya Hospital of Central South University | Completed | No outcome recorded |
| Phase 4 | NCT04840342 | Feb 2022 → Sep 2025 overdue | apparent mineralocorticoid excess, essential hypertension | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05155436 | Jan 2022 → Mar 2023 | hypertensive disorder, mineral metabolism disease | National Heart Foundation of Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT05165251 | Jan 2022 → Dec 2024 | — | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT04790279 | Apr 2021 → Dec 2022 | hypertension, pregnancy-induced | Prisma Health-Upstate | Completed | No outcome recorded |
| Phase 4 | NCT05089448 | Jan 2021 → Jun 2026 overdue | hypertensive disorder, substance abuse | Yan Li | Recruiting | No outcome recorded |
| Phase 4 | NCT04559074 | Oct 2020 → Nov 2021 | hypertensive disorder | Queen Mary University of London | Completed | No outcome recorded |
| Phase 4 | NCT06713785 | Sep 2020 → Jan 2021 | essential hypertension | Queen Mary University of London | Withdrawn | No outcome recorded |
| Phase 4 | NCT04111419 | Jul 2020 → Sep 2026 expected | atrial fibrillation, hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04330300 | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded |
| Phase 4 | NCT04085562 | Sep 2019 → Feb 2021 | renal hypertension | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT03978884 | Jun 2019 → May 2020 | diabetes mellitus, hypertensive disorder | The University of The West Indies | Withdrawn | No outcome recorded |
| Phase 4 | NCT03951207 | May 2019 → Sep 2021 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03667677 | Feb 2019 → Feb 2020 | anxiety, hypertensive disorder | Chongqing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03683069 | Jan 2019 → Aug 2023 | essential hypertension, genetic | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03666351 | Oct 2018 → Jul 2022 | aortic valve insufficiency, aortic valve stenosis, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT03626259 | Aug 2018 → Jan 2019 | hypertensive disorder | Centro Universitario de Ciencias de la Salud, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT03682692 | Jun 2018 → Jun 2021 | hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03474562 | Apr 2018 → Jun 2019 | atherosclerotic cardiovascular disease, hypertensive disorder, prediabetes syndrome | Yuhan Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03461003 | Apr 2018 → Nov 2020 | early onset hypertension | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03738761 | Feb 2018 → Sep 2019 | essential hypertension | KRKA | Completed | No outcome recorded |
| Phase 4 | NCT03319823 | Oct 2017 → Feb 2019 | hypertensive disorder | Cedars-Sinai Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT04521023 | Sep 2017 → Jan 2020 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT03294070 | Sep 2017 → Mar 2018 | hypertensive disorder | Centro Universitario de Ciencias de la Salud, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT03231982 | Apr 2017 → Apr 2019 | essential hypertension | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT02973035 | Dec 2016 → Jan 2020 | hypertensive disorder | Asan Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02847338 | Nov 2016 → Oct 2023 | hypertensive disorder | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT03747978 | Oct 2016 → May 2017 | hypertensive disorder, type 2 diabetes mellitus | Yaounde Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05467384 | Mar 2016 → Jun 2017 | hyperlipidemia, hypertensive disorder | Ayub Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02539810 | Sep 2015 → Dec 2016 | renal artery atheroma, resistant hypertension | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT04474899 | Jun 2015 → Feb 2024 | hypertensive disorder, obesity disorder | Royal Perth Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02378064 | May 2015 → Dec 2017 | atherosclerosis, coronary artery disorder | CHEOL WHAN LEE, M.D., Ph.D | Completed | No outcome recorded |
| Phase 4 | NCT01922141 | May 2015 → Jun 2018 | hypertensive disorder | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT02433119 | Mar 2015 → Sep 2016 | hypertensive disorder | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02377661 | Mar 2015 → May 2017 | hypertensive disorder | Wilhelminenspital Vienna | Completed | No outcome recorded |
| Phase 4 | NCT02353806 | Jan 2015 → Jul 2016 | hypertension, pregnancy-induced | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02062645 | Feb 2014 → Sep 2015 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02058446 | Oct 2013 → Mar 2014 | essential hypertension | TSH Biopharm Corporation Limited | Completed | No outcome recorded |
| Phase 4 | NCT01120327 | Sep 2011 → Dec 2014 | coronary artery disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01180413 | Dec 2010 → Apr 2012 | essential hypertension | Aarhus University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01198496 | Oct 2010 → Dec 2017 | essential hypertension, stroke disorder | Biomedis International Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01030458 | Sep 2010 → Mar 2012 | hypertensive disorder | KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT01190007 | Aug 2010 → Feb 2012 | hyperlipoproteinemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01828359 | Aug 2010 → Jan 2013 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT01167153 | May 2010 → Apr 2011 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01713920 | Apr 2010 → Sep 2014 | hypertensive disorder | Sang Hyun Ihm, MD PhD | Completed | No outcome recorded |
| Phase 4 | NCT01070030 | Jan → Oct 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01048047 | Nov → Dec 2009 | hypertensive disorder | University of Pavia | Unknown | No outcome recorded |
| Phase 4 | NCT01030081 | Oct 2009 → Mar 2013 | hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01394770 | Sep 2009 → Sep 2012 | hypertensive disorder | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT00931710 | Jul 2009 → Jan 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00902304 | Jul 2009 → Jul 2011 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00942994 | Jun 2009 → Mar 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01070043 | Jun 2009 → Sep 2010 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01241487 | Feb 2009 → Jan 2011 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00791258 | Nov 2008 → Aug 2009 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00819104 | Nov 2008 → Aug 2009 | essential hypertension | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00765947 | Sep 2008 → Aug 2009 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00654745 | May 2008 → Apr 2009 | essential hypertension, type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT01091753 | Mar 2008 → May 2009 | hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00921570 | Feb 2008 → May 2009 | hypertensive disorder, proteinuria, type 2 diabetes mellitus | Gulhane School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00538486 | Feb 2008 → Jun 2009 | hypertensive disorder, obesity disorder | Third Military Medical University | Completed | No outcome recorded |
| Phase 4 | NCT01738945 | Feb 2008 → May 2009 | — | Gulhane School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00700271 | Oct 2007 → Aug 2008 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00492128 | Sep 2007 → May 2009 | hypertensive disorder | Yokohama City University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01830517 | Aug 2007 → Jun 2011 | hypertensive disorder, ischemic stroke | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT00509470 | Jul 2007 → Jun 2012 | essential hypertension | Tokyo University | Completed | No outcome recorded |
| Phase 4 | NCT01375322 | Jun 2007 → Jun 2010 | hypertensive disorder, proteinuria, type 2 diabetes mellitus | TSH Biopharm Corporation Limited | Completed | No outcome recorded |
| Phase 4 | NCT00407537 | Mar 2007 → Oct 2009 | hyperlipoproteinemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00460915 | Jan 2007 → Jul 2009 | hypertensive disorder | Korea University Guro Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00412113 | Jan 2007 → Apr 2008 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00425997 | Dec 2006 → Oct 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00426478 | Nov 2006 → Sep 2007 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00523549 | Nov 2006 → Jan 2008 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00400777 | Aug 2006 → Nov 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00890591 | Aug 2006 → Jun 2007 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00351130 | Jun 2006 → Mar 2007 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00313547 | Apr 2006 → Apr 2007 | hypertensive disorder | Montreal Heart Institute | Terminated | No outcome recorded |
| Phase 4 | NCT00311155 | Mar 2006 → Apr 2008 | essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 4 | NCT00304226 | Feb 2006 → Jan 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00338338 | Nov 2005 → Sep 2007 | essential hypertension | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00242814 | Nov 2005 → Mar 2007 | hypertensive disorder, metabolic syndrome X | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00535925 | Oct 2005 → Dec 2011 | diabetic kidney disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT00185120 | Sep 2005 → Sep 2006 | hypertensive disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00174330 | May 2005 → Feb 2006 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00136851 | Dec 2004 → Jul 2005 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00741078 | Dec 2004 → Aug 2008 | hypertensive disorder | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00237588 | Dec 2004 → Jul 2005 | hypertensive disorder | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00174304 | Oct 2004 → Sep 2006 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00144144 | Sep 2004 → Sep 2008 | hypertensive disorder, type 2 diabetes mellitus | Advanced-J | Unknown | No outcome recorded |
| Phase 4 | NCT00139555 | Jul 2004 → Nov 2006 | hypertensive disorder, hypertensive heart disease | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00150384 | Jul 2004 → Aug 2005 | hyperlipidemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT07436104 | Jan 2004 → Dec 2015 | asthma, chronic diarrheal disease, chronic obstructive pulmonary disease, hypertensive disorder +2 | MAHAN Trust | Completed | No outcome recorded |
| Phase 4 | NCT00202618 | Dec 2003 → Jun 2006 | diabetes mellitus, hypertensive disorder, proteinuria | Shiga University | Unknown | No outcome recorded |
| Phase 4 | NCT00171054 | Sep 2003 → Oct 2007 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00136773 | Apr 2003 → Oct 2005 | proteinuria | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00159692 | Mar 2003 → Aug 2005 | hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00240474 | Dec 2002 → Mar 2004 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00367978 | Dec 2001 → Sep 2003 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00159718 | Jul 2001 → Jan 2007 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00143195 | Apr 2001 → Jan 2005 | myocardial ischemia | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00140985 | Feb 2000 → Jan 2002 | kidney disorder | Organon and Co | Completed | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT07679828 | Jul 2026 → Dec 2029 expected | diabetes mellitus, hyperlipidemia, hypertensive disorder | China Medical University, China | Not yet recruiting | No outcome recorded |
| — | NCT07099677 | Aug 2025 → Jun 2026 overdue | essential hypertension | Abant Izzet Baysal University | Recruiting | No outcome recorded |
| — | NCT06790927 | Feb 2025 → Dec 2026 expected | hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| — | NCT06780865 | Jan 2025 → Dec 2028 expected | chronic kidney disease, secondary hypertension | Shanghai Institute of Hypertension | Not yet recruiting | No outcome recorded |
| — | NCT05976438 | Aug 2023 → Dec 2024 | hypertensive disorder | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT07259733 | Jul 2023 → Dec 2026 expected | resistant hypertension | Instituto Dante Pazzanese de Cardiologia | Recruiting | No outcome recorded |
| — | NCT04521582 | Apr 2021 → Apr 2022 | essential hypertension | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| — | NCT03783754 | Aug 2018 → Mar 2021 | hypertensive disorder, intracerebral hemorrhage, vascular dementia | The George Institute | Terminated | No outcome recorded |
| — | NCT02474420 | Jun 2015 → Jun 2017 | beta thalassemia, disorder of iron metabolism and transport | Kevin H.M. Kuo, MD, MSc, FRCPC | Unknown | No outcome recorded |
| — | NCT02671695 | Apr 2015 → Apr 2018 | beta-thalassemia major | Tanta University | Completed | No outcome recorded |
| — | NCT02544776 | Jan → Aug 2015 | anovulation | Ahmed Fathy Ali Mohamed Ghanem | Completed | No outcome recorded |
| — | NCT01835418 | Apr 2013 → Jul 2014 | hypertensive disorder | Allina Health System | Unknown | No outcome recorded |
| — | NCT01658657 | Oct 2012 → Jul 2014 | hypertensive disorder, proteolytic capacity of plasma | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT01354613 | Apr 2011 → Dec 2013 | diastolic heart failure, hypertensive heart disease, lung disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00693199 | Jul → Oct 2006 | hypertensive disorder | Anhui Medical University | Completed | No outcome recorded |
| — | NCT00337298 | Jul 2006 → Feb 2009 | diabetic retinopathy, type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT00834600 | Dec 2005 → Oct 2011 | hypertensive disorder | The Louis & Rachel Rudin Foundation | Completed | No outcome recorded |
| — | NCT00656331 | Aug 2005 → Jun 2012 | hypertensive disorder | University of New Mexico | Withdrawn | No outcome recorded |
| — | NCT00518479 | Sep 2003 → Apr 2004 | hypertensive disorder, hypertensive heart disease | University of Leeds | Completed | No outcome recorded |
| — | NCT00382421 | Feb 1992 → Apr 2006 | myocardial ischemia | Luzerner Kantonsspital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 198 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06796660 Background | Sep 2025 → Dec 2027 expected | chronic kidney disease | Liu Zhanghong | Not yet recruiting | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT05667818 Comparator | Jan → Feb 2023 | hypertensive disorder | Overseas Pharmaceuticals, Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04329806 Comparator | Feb 2021 → Jul 2022 | abdominal obesity-metabolic syndrome | Italo Biaggioni | Terminated | No outcome recorded |
| Phase 1 | NCT04667624 Comparator | Feb → Apr 2020 | hypertensive disorder | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02608242 Comparator | Nov 2015 → Jun 2016 | hyperlipidemia, hypertensive disorder | Yuhan Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT02496910 Comparator | Jun → Sep 2015 | hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03009474 Comparator | Feb → Apr 2015 | hyperlipidemia, hypertensive disorder | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02183675 Comparator | Jul → Oct 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02166398 Comparator | Jun → Oct 2014 | — | Korea United Pharm. Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03648333 Comparator | Dec 2013 → Feb 2014 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01819779 Comparator | Mar → May 2013 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01806311 Comparator | Dec 2012 → Aug 2013 | hypertensive disorder | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01652339 Comparator | Jul → Aug 2012 | — | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01494727 Comparator | Feb → Apr 2012 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01337674 Background | Apr → Nov 2011 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01278797 Comparator | Jan → Feb 2011 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01177293 Comparator | Mar → Jun 2010 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00938197 Comparator | Jun → Aug 2009 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00626743 Background | May 2008 → May 2009 | hypertensive disorder | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05312892 Comparator | May 2022 → Dec 2028 expected | hypertensive disorder, obesity disorder | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02834403 Background | Nov 2016 → Jan 2021 | triple-negative breast carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07064525 Comparator | Dec 2024 → Dec 2025 overdue | advanced heart failure, diabetes mellitus, essential hypertension, moderate heart failure | Shin Poong Pharmaceutical Co. Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05212597 Comparator | Jan 2022 → Dec 2023 | aortic valve insufficiency | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT05103332 Background | Nov 2021 → Dec 2023 | essential hypertension | Alnylam Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04218552 Comparator | Feb 2020 → Feb 2021 | essential hypertension | Addpharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03897868 Comparator | Mar 2019 → Feb 2020 | essential hypertension | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 2 | NCT02966717 Comparator | Aug → Oct 2016 | chronic kidney disease, nephrotic syndrome | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01870739 Background | Oct 2013 → Jun 2015 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01996449 Comparator | Jul 2013 → Apr 2021 | hypertensive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01692301 Background | Dec 2012 → Apr 2015 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01631864 Comparator | Oct 2012 → Jul 2013 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01614366 Background | Jul 2012 → May 2014 | essential hypertension | TSH Biopharm Corporation Limited | Completed | No outcome recorded |
| Phase 2 | NCT01118520 Comparator | Sep 2011 → Apr 2015 | abdominal aortic aneurysm | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT01256411 Background | Nov 2010 → Apr 2012 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01080768 Comparator | Feb → Nov 2010 | hypertensive disorder | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00950066 Comparator | Jul 2009 → Jan 2010 | essential hypertension | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00417170 Comparator | Oct 2007 → Jul 2010 | hypertensive disorder, metabolic syndrome X | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00498433 Comparator | Jun 2007 → Mar 2012 | abdominal obesity-metabolic syndrome, hypertensive disorder | Novartis | Terminated | No outcome recorded |
| Phase 346 trials | ||||||
| Phase 3 | NCT06646354 Comparator | Apr → May 2025 overdue | essential hypertension, hyperlipoproteinemia | Hyundai Pharm | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06150560 Comparator | Apr 2024 → Jun 2028 expected | aorta coarctation, hypertensive disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 3 | NCT05920005 Comparator | Aug 2023 → Mar 2025 | hypertensive disorder | Hospital Israelita Albert Einstein | Completed | No outcome recorded |
| Phase 3 | NCT05144360 Comparator | Aug 2022 → Jul 2024 | hypertensive disorder, type 2 diabetes mellitus | EMS | Withdrawn | No outcome recorded |
| Phase 3 | NCT07116863 Comparator | Jun 2022 → Jun 2024 | essential hypertension | Kyungdong Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04121299 Comparator | Jul 2021 → Jun 2026 | hypertensive disorder | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 3 | NCT06465264 Comparator | Apr 2021 → Aug 2022 | essential hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04074551 Comparator | Jul 2019 → Mar 2020 | hyperlipidemia, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT03660397 Background | Aug 2018 → Jul 2019 | hypertensive disorder | Third Military Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03653845 Background | Jul 2018 → Jul 2019 | hypertensive disorder, primary aldosteronism | Third Military Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT05288400 Comparator | May → Dec 2018 | essential hypertension | Servier | Completed | No outcome recorded |
| Phase 3 | NCT03082014 Comparator | Feb 2018 → Jul 2022 | cerebrovascular disorder | Ludwig-Maximilians - University of Munich | Terminated | No outcome recorded |
| Phase 3 | NCT03639480 Comparator | Oct 2017 → Oct 2018 | hyperlipidemia, hypertensive disorder | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT03156842 Comparator | May 2017 → Dec 2018 | essential hypertension, hyperlipidemia | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03536598 Comparator | Oct 2016 → Sep 2017 | hyperlipidemia, combined, 2 | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02900729 Background | Oct 2016 → Aug 2017 | hypertensive disorder | Shanghai WiseGain Medical Devices Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02586311 Comparator | Jan → Aug 2016 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT02620163 Comparator | Dec 2015 → Dec 2016 | essential hypertension | Yuhan Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02738632 Background | May 2015 → Aug 2016 | essential hypertension | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02916602 Background | Apr 2015 → Sep 2016 | hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT02896621 Comparator | Dec 2014 → Feb 2016 | hypertensive disorder, obstructive sleep apnea syndrome | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT01896661 Comparator | Dec 2014 → Dec 2015 | hypertensive disorder, obstructive sleep apnea syndrome | Hospital de Clinicas de Porto Alegre | Completed | No outcome recorded |
| Phase 3 | NCT02587988 Comparator | Sep 2014 → May 2015 | erectile dysfunction, hypertensive disorder | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT01975246 Comparator | Nov 2013 → Jun 2014 | essential hypertension | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02644395 Comparator | Jan 2013 → Dec 2015 | secondary hypertension | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01663233 Background | Aug 2012 → May 2013 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01556997 Comparator | Feb 2012 → Feb 2013 | essential hypertension | Symplmed Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 3 | NCT01365481 Background | Aug 2011 → Sep 2015 | chronic kidney disease, hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01302691 Background | Jan 2011 → Apr 2012 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01286558 Comparator | Jan → Sep 2011 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01237223 Comparator | Oct 2010 → May 2011 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01103960 Comparator | Jul 2010 → Aug 2011 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00902538 Background | Apr 2009 → Sep 2010 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00860262 Comparator | Mar → Dec 2009 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00877929 Comparator | Feb 2009 → May 2010 | hypertensive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00841672 Comparator | Jan → Sep 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00891267 Comparator | Oct 2008 → Apr 2011 | hypertensive disorder, metabolic syndrome X | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT00659451 Comparator | Apr 2008 | diabetes mellitus, essential hypertension | University of Pavia | Unknown | No outcome recorded |
| Phase 3 | NCT00627952 Comparator | Nov 2007 → Dec 2008 | hypertensive disorder | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 3 | NCT00591266 Background | Oct 2007 → Mar 2009 | essential hypertension | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00530946 Comparator | Sep 2007 → Apr 2008 | hyperlipoproteinemia, hypertensive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00413049 Comparator | Jan → Nov 2007 | essential hypertension | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00368277 Background | Sep 2006 → Feb 2008 | essential hypertension | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00360178 Background | Jul → Dec 2006 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00220233 Background | Apr 2005 → Aug 2007 | essential hypertension | Sankyo Pharma Gmbh | Completed | No outcome recorded |
| Phase 3 | NCT06395194 Comparator | Sep 1997 → Sep 2003 | essential hypertension | Oslo University Hospital | Completed | No outcome recorded |
| Phase 487 trials | ||||||
| Phase 4 | NCT07687160 Comparator | Sep 2026 → Feb 2028 expected | hypertensive disorder | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07241338 Comparator | Nov 2025 → Nov 2026 expected | essential hypertension | Jing Liu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06523465 Background | Sep 2024 → Dec 2025 overdue | hypertensive disorder, primary aldosteronism | Third Military Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT05416840 Comparator | Jan 2024 → Nov 2026 expected | hypertensive disorder | Jing Liu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06041529 Comparator | Oct 2023 → Feb 2026 overdue | essential hypertension | Yuhan Corporation | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07327749 Comparator | Oct 2022 → Dec 2024 | hypertensive disorder | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT05275907 Comparator | Jul 2022 → Oct 2023 | hypertensive disorder, impaired renal function disease | Northwestern University | Withdrawn | No outcome recorded |
| Phase 4 | NCT05513937 Comparator | May → Nov 2022 | hypertensive disorder | Menarini International Operations Luxembourg SA | Completed | No outcome recorded |
| Phase 4 | NCT05169021 Comparator | Dec 2021 → Dec 2024 overdue | stroke disorder | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04434664 Comparator | Dec 2021 → Dec 2024 | diastolic heart failure, hypertensive disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT04929600 Comparator | Nov 2021 → Jun 2023 | essential hypertension | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT05279807 Comparator | Oct 2021 → Apr 2022 | hypertensive disorder | Menarini International Operations Luxembourg SA | Completed | No outcome recorded |
| Phase 4 | NCT04978649 Comparator | Sep 2021 → Jul 2026 | hypertensive disorder, type 2 diabetes mellitus | Guangdong Provincial People's Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT04306627 Comparator | Apr → Oct 2020 | essential hypertension, hyperlipidemia | Yerevan State Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT04120753 Comparator | Aug 2019 → Jul 2021 | hyperlipidemia, hypertensive disorder | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 4 | NCT03860220 Comparator | Apr 2019 → Sep 2023 | hyperlipidemia, hypertensive disorder | Hyo-Soo Kim | Completed | No outcome recorded |
| Phase 4 | NCT03054467 Comparator | Dec 2018 → Apr 2019 | — | Kosin University Gospel Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03990480 Comparator | Dec 2018 → Apr 2019 | essential hypertension | Damanhour University | Completed | No outcome recorded |
| Phase 4 | NCT03476616 Background | Sep 2018 → Jun 2025 | essential hypertension, obesity disorder | Hippocration General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03946514 Comparator | Sep 2018 → Aug 2024 | hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03847506 Comparator | Jul 2018 → Dec 2020 | hyperlipidemia | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03264352 Comparator | Feb 2018 → Sep 2025 overdue | hypertensive disorder, type 2 diabetes mellitus | XueQing Yu | Recruiting | No outcome recorded |
| Phase 4 | NCT03047538 Comparator | Sep 2017 → Dec 2019 | hyperlipidemia, hypertensive disorder | Charles University, Czech Republic | Withdrawn | No outcome recorded |
| Phase 4 | NCT02742467 Comparator | Jun 2017 → Jun 2018 | hypertensive disorder | University of Abuja | Completed | No outcome recorded |
| Phase 4 | NCT03578042 Comparator | Apr 2017 → Sep 2019 | hypertensive disorder | Hotel Dieu de France Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02774460 Comparator | Feb 2017 → Jun 2021 | hypertensive disorder | Uppsala University | Completed | No outcome recorded |
| Phase 4 | NCT02940548 Comparator | Dec 2016 → Dec 2020 | essential hypertension | Jing Liu | Terminated | No outcome recorded |
| Phase 4 | NCT02710552 Comparator | Apr 2016 → Mar 2019 | hypertensive disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02710539 Comparator | Apr 2016 → Mar 2019 | hypertensive disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02996916 Comparator | Dec 2015 → Dec 2018 | — | Kurume University | Unknown | No outcome recorded |
| Phase 4 | NCT02817503 Background | Dec 2015 → Dec 2016 | hyperhomocysteinemia, hypertensive disorder | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 4 | NCT02734355 Comparator | Nov 2015 → Jan 2016 | atrial fibrillation | Research Institute for Complex Problems of Cardiovascular Diseases, Russia | Completed | No outcome recorded |
| Phase 4 | NCT03106597 Comparator | Aug 2015 → May 2018 | essential hypertension | Korea University Guro Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT03195023 Comparator | Jun 2015 → Dec 2019 | chronic kidney disease, proteinuria | Hospital General Universitario Gregorio Marañon | Unknown | No outcome recorded |
| Phase 4 | NCT02373163 Comparator | Sep 2014 → Mar 2016 | hypertensive disorder | Prevencion | Completed | No outcome recorded |
| Phase 4 | NCT02294539 Comparator | Aug 2014 → May 2016 | hypertensive disorder | Chong-Jin Kim | Completed | No outcome recorded |
| Phase 4 | NCT02213224 Comparator | Aug 2014 → Sep 2016 | NAFLD1 | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02995954 Comparator | Jan 2014 → Dec 2015 | essential hypertension | Guido Iaccarino | Completed | No outcome recorded |
| Phase 4 | NCT02034435 Comparator | Oct 2013 → Dec 2019 | metabolic syndrome X | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02058823 Comparator | Aug 2013 → Jul 2014 | obstructive sleep apnea syndrome | University Hospital, Grenoble | Terminated | No outcome recorded |
| Phase 4 | NCT01964079 Comparator | Apr 2013 → Apr 2017 | hypertensive disorder | Wonju Severance Christian Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02046395 Background | Jan 2012 → Dec 2019 | hypertensive disorder, type 2 diabetes mellitus | Tulane University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01490255 Comparator | Jan 2012 → Jun 2014 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT00987662 Comparator | Jan 2012 → Jan 2013 | hypertensive disorder, obesity disorder | Aristotle University Of Thessaloniki | Withdrawn | No outcome recorded |
| Phase 4 | NCT01500590 Comparator | Nov 2011 → Aug 2018 | hypertensive disorder, type 2 diabetes mellitus | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT01277822 Comparator | May 2011 → Apr 2013 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT01368536 Comparator | May 2011 → Feb 2012 | hypertensive disorder, type 2 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT01922687 Comparator | Apr 2011 → Mar 2014 | arterial disorder | Shanghai Institute of Hypertension | Unknown | No outcome recorded |
| Phase 4 | NCT01409408 Comparator | Apr 2011 → Apr 2013 | hypertensive disorder, type 2 diabetes mellitus | Hospital Universitario Pedro Ernesto | Withdrawn | No outcome recorded |
| Phase 4 | NCT01180205 Comparator | Aug 2010 → Oct 2011 | hypertensive disorder | Johannes Gutenberg University Mainz | Unknown | No outcome recorded |
| Phase 4 | NCT01203696 Comparator | Jul 2010 → Apr 2011 | coronary artery disorder | Ruttonjee Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01176032 Background | Jun 2010 → Apr 2013 | hypertensive disorder, hypertensive heart disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01271374 Comparator | Apr 2010 → Jun 2011 | hypertensive disorder | InVasc Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT01101009 Comparator | Apr 2010 → Nov 2012 | hypertensive disorder | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 4 | NCT01131546 Comparator | Dec 2009 → Mar 2011 | essential hypertension | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00438113 Comparator | Dec 2009 → Sep 2016 | atrial fibrillation | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 4 | NCT00805311 Background | Apr 2009 → May 2014 | atherosclerosis, carotid stenosis, stroke disorder | Russian Cardiology Research and Production Center | Terminated | No outcome recorded |
| Phase 4 | NCT01819220 Comparator | Apr 2009 → Nov 2014 | hypertensive disorder | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00853957 Comparator | Feb → Aug 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00787605 Comparator | Nov 2008 → Jan 2010 | diabetes mellitus, hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00741585 Comparator | Sep 2008 → Jun 2018 | chronic kidney disease, essential hypertension, stroke disorder | University of Vigo | Completed | No outcome recorded |
| Phase 4 | NCT00739596 Comparator | Jul 2008 → Mar 2009 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00847262 Comparator | Jun → Dec 2008 | diabetes mellitus, hypertensive disorder, obesity disorder | Third Military Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00669435 Comparator | Apr 2008 | hypertensive disorder | University of Pavia | Unknown | No outcome recorded |
| Phase 4 | NCT00666536 Comparator | Mar 2008 → Jan 2009 | hypertensive disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT00542269 Background | Mar 2008 → Jul 2009 | metabolic syndrome X | Novartis | Terminated | No outcome recorded |
| Phase 4 | NCT00818779 Comparator | Jan 2008 → Aug 2011 | coronary artery disorder, type 2 diabetes mellitus | Texas Tech University Health Sciences Center | Completed | No outcome recorded |
| Phase 4 | NCT00687973 Comparator | Jan 2008 → Jan 2009 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01011660 Comparator | Oct 2007 → Aug 2012 | essential hypertension | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00454662 Comparator | Apr 2007 → Sep 2011 | diabetes mellitus, hypertensive disorder | COLM Study Research Organization | Completed | No outcome recorded |
| Phase 4 | NCT00439738 Comparator | Dec 2006 → Nov 2007 | hypertensive disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT00294567 Comparator | Dec 2005 → May 2009 | coronary atherosclerosis, hypertensive disorder | Juntendo University | Completed | No outcome recorded |
| Phase 4 | NCT00661895 Background | Aug 2005 → Aug 2009 | hypertensive disorder | Creighton University | Completed | No outcome recorded |
| Phase 4 | NCT00134160 Comparator | Aug 2005 → May 2010 | hypertensive disorder | OSCAR Study | Completed | No outcome recorded |
| Phase 4 | NCT00224549 Background | Apr 2005 → Aug 2009 | essential hypertension | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT00421863 Background | Feb 2005 → Jan 2009 | hypertensive disorder | Heart Care Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00129233 Comparator | Oct 2004 → Jul 2010 | hypertensive disorder, type 2 diabetes mellitus | Nagoya University | Completed | No outcome recorded |
| Phase 4 | NCT00754429 Comparator | Jun 2004 → Jun 2009 | ischemic stroke | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| Phase 4 | NCT01518855 Comparator | Mar 2004 → Apr 2005 | essential hypertension | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00234871 Comparator | Jan 2004 → Mar 2005 | diabetes mellitus, hypertensive disorder, proteinuria | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00140959 Background | Feb 2003 → Jun 2004 | hypertensive disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00772499 Comparator | Nov 2002 → Jul 2005 | essential hypertension | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT00124969 Comparator | Jan 2002 → Oct 2006 | chronic renal failure syndrome | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00198562 Comparator | Apr 2000 → Mar 2012 | hypertensive disorder | Ministry of Health, Labour and Welfare, Japan | Unknown | No outcome recorded |
| Phase 4 | NCT03276598 Comparator | Nov 1999 → Apr 2004 | essential hypertension | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00813722 Comparator | Mar 1999 → Jan 2009 | hypertensive disorder | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT01089452 Comparator | — | hypertensive disorder | Monash University | Withdrawn | No outcome recorded |
| Phase not applicable27 trials | ||||||
| — | NCT07683585 Comparator | Apr → Jul 2026 overdue | coronary artery disorder, hypertensive disorder | National Medical Research Center for Therapy and Preventive Medicine | Recruiting | No outcome recorded |
| — | NCT07458880 Comparator | Mar 2026 → Sep 2029 expected | intracerebral hemorrhage | The University of Hong Kong | Recruiting | No outcome recorded |
| — | NCT05684055 Comparator | Sep 2023 → May 2025 overdue | hypertensive disorder | University Hospital, Basel, Switzerland | Active not recruiting | No outcome recorded |
| — | NCT05479097 Background | Feb → Aug 2023 | hypertensive disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT05679102 Comparator | Dec 2022 → Jan 2023 | — | Himayat Ullah | Completed | No outcome recorded |
| — | NCT05552300 Background | Oct 2022 → Oct 2024 | resistant hypertension | First Affiliated Hospital of Chengdu Medical College | Unknown | No outcome recorded |
| — | NCT05398393 Background | Jan 2022 → Jun 2023 | chronic hepatitis B virus infection, lip disorder | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| — | NCT04040634 Background | Aug 2019 → May 2026 overdue | cognitive disorder, diabetes mellitus, hypertensive disorder | Hospital Israelita Albert Einstein | Active not recruiting | No outcome recorded |
| — | NCT04036409 Background | Aug 2019 → May 2026 overdue | cognitive disorder, hypertensive disorder, ischemic stroke | Hospital Israelita Albert Einstein | Active not recruiting | No outcome recorded |
| — | NCT03956823 Comparator | Aug 2019 → May 2021 | essential hypertension | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT03626506 Background | Feb 2019 → Aug 2020 | hypertensive disorder | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT03015311 Background | Jan 2017 → Dec 2020 | essential hypertension | Chinese Academy of Medical Sciences, Fuwai Hospital | Unknown | No outcome recorded |
| — | NCT02364089 Comparator | Apr 2015 → Mar 2022 | adrenal gland disorder | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT02312375 Comparator | Mar 2015 → Dec 2016 | hypertensive disorder, type 2 diabetes mellitus | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT02121041 Comparator | May 2014 → Sep 2015 | hypertensive disorder | Anthony J Viera, MD, MPH | Completed | No outcome recorded |
| — | NCT02412761 Comparator | Jun 2013 → Jul 2016 | essential hypertension | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| — | NCT01996085 Comparator | Jan 2013 → Jun 2016 | hypertensive disorder | Military Institute od Medicine National Research Institute | Completed | No outcome recorded |
| — | NCT01762501 Comparator | Dec 2012 → Dec 2013 | essential hypertension | Sogo Rinsho Médéfi Co., Ltd. | Completed | No outcome recorded |
| — | NCT01748253 Comparator | Nov 2012 → Oct 2013 | atrial fibrillation | Acrobat Trial Group | Unknown | No outcome recorded |
| — | NCT01665235 Comparator | Aug 2012 → Aug 2014 | cerebral artery stenosis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT01425242 Comparator | Sep 2011 → Dec 2013 | abdominal aortic aneurysm, essential hypertension | Amsterdam UMC, location VUmc | Terminated | No outcome recorded |
| — | NCT01252238 Comparator | Jun 2010 → Dec 2012 | — | Brigham and Women's Hospital | Terminated | No outcome recorded |
| — | NCT00825188 Comparator | Jan 2009 → Mar 2014 | hypertensive disorder, obesity disorder | University of Mississippi Medical Center | Terminated | No outcome recorded |
| — | NCT00691314 Comparator | Jun 2008 → Sep 2010 | atherosclerosis, transient ischemic attack | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00664846 Background | Apr 2008 → Dec 2010 | ischemic stroke | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00229242 Comparator | Nov 2003 → Dec 2006 | hypertensive disorder | Queen's University | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-06-18 | Takeda | Zacras ® Combination Tablets LD and Zacras ® Combination Tablets HD, Fixed-Dose Combination of Azilsartan and Amlodipine, and Azilva ® Tablets 10mg, Treatment for Hypertension, are Now Available in Japan takeda.com ↗ |
| 2007-07-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Amlodipine Besylate Tablets tevapharm.com ↗ |
| 2007-05-22 | Daiichi Sankyo | Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007) First Release of Data for New Combination daiichisankyo.com ↗ |
| 2006-11-29 | Daiichi Sankyo | DAIICHI SANKYO, INC. ANNOUNCES FILING OF NEW DRUG APPLICATION FOR AMLODIPINE BESYLATE / OLMESARTAN MEDOXOMIL COMBINATION FOR THE TREATMENT OF HYPERTENSION daiichisankyo.com ↗ |
| 2005-03-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Amlodipine Besylate Tablets tevapharm.com ↗ |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 560 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amlodipine | “The purpose of this study is to assess the pharmacokinetic characteristics of olmesartan and S-amlodipine after single oral administration of Sevikar tab. 10/40mg, a...” NCT02955498 ↗537“The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged,...” NCT04040634 ↗ “Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC)...” NCT06275763 ↗ “The antihypertensive effect of the increased dose of angiotensin II receptor blocker (AII antagonist) is compared with that of the additional combined use of amlodipine in...” NCT00144144 ↗ “The dosages were SPC1001 High (4/2.5/1.25 mg), SPC1001 Mid1 (2.67/1.67/0.83 mg), SPC1001 Mid2 (4/1.25/1.25 mg), SPC1001 Low (2/1.25/0.625 mg), SPC3001 (candesartan 8 mg),...” PMID 41162308 ↗ Oct 2025 “The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment...” NCT01190007 ↗ “We investigated the blood pressure (BP) lowering efficacy of two dual antihypertensive therapies, the amlodipine/benazepril and benazepril/hydrochlorothiazide combinations,...” PMID 41053442 ↗ Oct 2025 “Patients whose blood pressure (BP) remained uncontrolled were randomized double-blind to fixed-dose losartan 50 mg/hydrochlorothiazide 12.5 mg/amlodipine 5 mg (L50/H12.5/A5) or...” PMID 25271811 ↗ Oct 2014 “Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using...” NCT02966717 ↗ “The aim of this study was to evaluate the efficacy of olmesartan/amlodipine (OLM/AML) single-pill combination (SPC) therapy using ambulatory blood pressure monitoring (ABPM) in...” PMID 39504016 ↗ Nov 2024 “To evaluate the efficacy and safety of amlodipine besylate and candesartan cilexetil administered in a fixed-dose combination tablet versus co-administered as their separate...” NCT03231982 ↗ “Pharmacokinetics of a Fixed-Dose Combination Product of Amlodipine, Losartan, Ezetimibe, and Rosuvastatin and Its Comparison with Co-administration of Four Individual...” PMID 38775910 ↗ May 2024 “olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for...” NCT01613209 ↗ “Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based...” PMID 19960134 ↗ Dec 2009 “In intervention clusters, lay CHWs independently prescribed and titrated a fixed-dose combination of amlodipine and hydrochlorothiazide, guided by a mobile clinical decision...” PMID 41680483 ↗ Feb 2026 “The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and...” PMID 29150250 ↗ Nov 2017 “This study aimed to evaluate the long-term safety and efficacy of a triple combination therapy with 20 mg azilsartan (AZL), 5 mg amlodipine (AML) and 12.5 mg hydrochlorothiazide (HCTZ).” PMID 29235365 ↗ Dec 2017 “amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily” NCT01500590 ↗ “Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).” NCT04978649 ↗ “Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).” NCT03264352 ↗ “Blood Pressure Control: Antihypertensive drugs such as amlodipine tablets (5 mg qd), nifedipine tablets (30 mg qd), or losartan tablets (100 mg qd) can be selected.” NCT06796660 ↗ “Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.” NCT02817503 ↗ “Participants received either a quadpill of candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg or candesartan 8 mg for 12 weeks.” PMID 38584159 ↗ Apr 2024 “Therefore, we sought to identify predictors of significant hsCRP reduction after the use of rosuvastatin (RSV)/amlodipine (AML) and atorvastatin (ATV)/AML.” PMID 40429358 ↗ May 2025 “preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine” NCT04036409 ↗ “In this study, candesartan cilexetil, amlodipine, and atorvastatin was administered orally as FDCs of 16/10/40 mg in study 1 and 16/5/20 mg in study 2.” PMID 38771476 ↗ May 2024 “Fixed-dose combination tablet containing valsartan 160 mg and amlodipine 10 mg. Orally administered once daily for 6 weeks during Treatment Period 2.” NCT07116863 ↗ “Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg” NCT01394770 ↗ “telmisartan 40 mg/amlodipine 5 mg/rosuvastatin 10 mg (TEL/ALD/RSV) or amlodipine 5 mg/atorvastatin 10 mg (ALD/ATV) after washout/run-in period” PMID 38380420 ↗ Feb 2024 “The aim of this study was to compare the pharmacokinetics (PKs) of candesartan, amlodipine, and atorvastatin FDC versus separate tablets.” PMID 41970000 ↗ Mar 2026 “Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet.” NCT01838850 ↗ “Candesartan/Hydrochlorothiazide(Candemore Plus® Tab) Versus Candesartan/Amlodipine(Cantabell® Tab) in Hypertensive Patients” NCT04521023 ↗ “Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together” NCT05077462 ↗ “free monocomponents of Amlodipine 5 mg, Bisoprolol fumarate 5 mg and Perindopril arginine 5 mg given concomitantly” NCT05288400 ↗ “amlodipine group will receive low dose oral amlodipine ( 5 mg ) before iv contrast and every 12 hour for 48 hour” NCT07291375 ↗ “Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP \> 140mmHg or DBP \> 90mmHg at week 12)” NCT03474562 ↗ “Amlodipine is a drug which belongs to calcium channel blockers (CCBs) and is used to treat hypertension.” NCT04667624 ↗ “Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.” NCT04929600 ↗ “Participants will receive a calcium channel blocker (e.g., Amlodipine) for antihypertensive treatment.” NCT07099677 ↗ “a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension” PMID 32003938 ↗ Jan 2020 “combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)” NCT02069821 ↗ “Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg” NCT03009474 ↗ “Amlodipine, diltiazem, felodipine, nicardipine, nifedipine, nimodipine, nitrendipine, verapamil” NCT04330300 ↗ “fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide” NCT07064525 ↗ “A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg” NCT01823913 ↗ “Drug: TELMISARTAN Telmisartan + Amlodipine 40 + 5/80 +5 mg 1 coated tablet, once a day” NCT05144360 ↗ “1 capsule of Amlodipine 2.5 mg daily and 3 capsules of Amlodipine placebo daily” NCT06236061 ↗ “prescription of antihypertensives (amlodipine and/or losartan OR enalapril)” NCT05479097 ↗ “High-resistance type: Amlodipine Besylate Tablets 5mg, once daily, orally.” NCT07240909 ↗ “Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide” NCT03629067 ↗ “antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day” NCT00691314 ↗ “antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day” NCT00664846 ↗ “Fixed-dose combination (FDC) of perindopril/amlodipine, tablets.” NCT03738761 ↗ “JLP-1401(Telmisartan 80 mg, amlodipine 5 mg, rosuvastatin 5 mg)” NCT03707899 ↗ “Exforge® 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)” NCT01776047 ↗ “irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d” NCT03660397 ↗ “* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg” NCT02364089 ↗ “irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d” NCT05552300 ↗ “Fixed Dose combination of Perindopril/Indapamide/Amlodipine” NCT05820880 ↗ “verapamil, amlodipine, felodipine, isradipine, nicardipine” NCT00684489 ↗ “Subjects received amlodipine 10mg once daily for 10 days.” NCT01341392 ↗ “amlodipine besylate (10mg as amlodipine), valsartan 160mg” NCT03648333 ↗ “olmesartan medoxomil/amlodipine at 10/2.5 mg or 20/5 mg” NCT07679828 ↗ “Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg” NCT03024476 ↗ “telmisartan/amlodipine/chlorthalidone 20/2.5/6.25 mg” PMID 41717679 ↗ Feb 2026 “C52R1H(FDC, Valsartan/Amlodipine) 160/10 mg tablet” NCT05077475 ↗ “Amlodipine 5 mg is preferred for selected patients” NCT06790927 ↗ “Amlodipine orotate 10mg/Olmesartan medoxomil 40mg” NCT02058472 ↗ “exforge 10/160mg(amlodipine 10mg, valsartan160mg)” NCT02060019 ↗ “adding on Telmisartan 40 mg and Amlodipine 5 mg.” NCT03319823 ↗ “Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg” NCT01237873 ↗ “Amlodipine 10 mg daily, taking in the morning” NCT01896661 ↗ “Amlodipine orotate 6.91mg (5mg as amlodipine)” NCT02433119 ↗ “* amlodipine besylate (10mg as amlodipine)” NCT01819779 ↗ “Amlodipine is continuously administered.” NCT00509470 ↗ “amlodipine 5-10 mg/d ; terazosin 2-6mg/d” NCT03653845 ↗ “amlodipine, Losartan, Chlorthalidone FDC” NCT02916602 ↗ “consisting of Amlodipine and Indapamide” NCT06012487 ↗ “amlodipine therapy (NORVASC 10 mg/day)” NCT03054467 ↗ “Telmisartan/Amlodipine 80/10mg (FDC)” NCT02608242 ↗ “amlodipine(5mg,QD)+Vytorin(10mg,QD)” NCT02378064 ↗ “addition of amlodipine (C) 10mg od” NCT03476616 ↗ “amlodipine besylate tablet 2.5mg” NCT05377203 ↗ “Amlodipine 10mg/Valsartan 160mg” NCT04185090 ↗ “Amlodipine 5mg /Losartan 100mg” NCT01828359 ↗ “Telmisartan/Amlodipine 80/5mg” NCT02951962 ↗ “amlodipine 2.5 mg (AML 2.5)” PMID 42130156 ↗ May 2026 “Amlodipine 5mg(Norvasc)” NCT04081844 ↗ “amlodipine 10 mg/d” NCT02539810 ↗ “Drug: Amlodipine” NCT01180205 ↗ “Amlodipine (AM)” NCT01614366 ↗ “Amlodipine” NCT00741585 ↗ |
| Known as | ALD | “fimasartan 60 mg/amlodipine 10 mg + rosuvastatin 20 mg (FMS/ALD + RSV) as study group” PMID 36451242 ↗ Dec 2022 |
| Known as | AML | “The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the...” PMID 28734660 ↗ Jul 201711“OBJECTIVE: The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a...” PMID 20678674 ↗ Jul 2010 “OBJECTIVE: To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ)...” PMID 23721363 ↗ Jul 2013 “This study aimed to assess the efficacy and safety of a combination therapy of Allisartan Isoproxil 240 mg and Amlodipine 5 mg (ALI/AML) compared to AML 5 mg monotherapy in...” PMID 39821945 ↗ Jan 2025 “Central blood pressure (BP), an important measure of cardiovascular risk, has been shown to be effectively reduced by calcium channel blockade with amlodipine (AML) plus...” PMID 24293132 ↗ Nov 2013 “This study aimed to evaluate the long-term safety and efficacy of a triple combination therapy with 20 mg azilsartan (AZL), 5 mg amlodipine (AML) and 12.5 mg hydrochlorothiazide (HCTZ).” PMID 29235365 ↗ Dec 2017 “Therefore, we sought to identify predictors of significant hsCRP reduction after the use of rosuvastatin (RSV)/amlodipine (AML) and atorvastatin (ATV)/AML.” PMID 40429358 ↗ May 2025 “Both Olmesartan (OLM)/Amlodipine (AML) combination and Hydrochlorothiazide (HCTZ) have proven to be efficacious and safe in lowering blood pressure” NCT00902538 ↗ “Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet.” NCT01838850 ↗ “This study aimed to evaluate the efficacy and tolerability of irbesartan (IRB) and amlodipine (AML) combination therapy” PMID 38704294 ↗ May 2024 “amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm” PMID 23254596 ↗ Dec 2012 “Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ” NCT00523744 ↗ |
| Known as | Amlo | “triple-combination of olmesartan/amlodipine/rosuvastatin (Olme/Amlo/Rosu)” PMID 37814541 ↗ Jan 2023 |
| Known as | Amlodin | “compared with those of amlodipine besilate (Norvasc or Amlodin)” NCT00294567 ↗ |
| Known as | Amlodipine (AM) | “Amlodipine (AM)” NCT01614366 ↗ |
| Known as | Amlodipine and Hydrocholorothiazide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00656331 ↗ |
| Known as | amlodipine besilate | “Study to determine the potential pharmacokinetic interaction of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate and amlodipine as amlodipine besilate at...” NCT04245046 ↗2“compared with those of amlodipine besilate (Norvasc or Amlodin)” NCT00294567 ↗ “amlodipine as amlodipine besilate” NCT04262765 ↗ |
| Known as | amlodipine besylate | “The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the...” PMID 28734660 ↗ Jul 201720“OBJECTIVE: The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a...” PMID 20678674 ↗ Jul 2010 “This study is being performed to determine the bioavailability, or extent of absorption into the body, of a 10 mg amlodipine besylate orally disintegrating tablet (ODT) as...” NCT01138826 ↗ “The objective of this study is to compare the rate and extent of absorption of amlodipine from a test formulation of Amlodipine Besylate Tablets, 10 mg versus the reference...” NCT00841815 ↗ “Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion” NCT00407537 ↗ “Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once” NCT02739672 ↗ “Test preparation (T): amlodipine besylate controlled-release tablets Specification: 5 mg Batch No.: 22102501 Content: 100.9%” NCT05667818 ↗ “For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy.” NCT03015311 ↗ “the calcium channel blocker amlodipine besylate and the nonsteroidal anti-inflammatory drug (NSAID) celecoxib” NCT02172040 ↗ “Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.” NCT00170950 ↗ “A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg” NCT01823913 ↗ “the calcium channel blocker called amlodipine besylate (at dose of 10mg)” NCT05275907 ↗ “Amlodipine besylate 13.87 mg (Amlodipine 10 mg)” NCT03032315 ↗ “amlodipine besylate/benazepril hydrochloride” NCT00136851 ↗ “* amlodipine besylate (10mg as amlodipine)” NCT01819779 ↗ “* amlodipine besylate (10mg as amlodipine)” NCT01652339 ↗ “amlodipine besylate tablet 2.5mg” NCT05377203 ↗ |
| Known as | Amlodipine Besylate Tablets | “High-resistance type: Amlodipine Besylate Tablets 5mg, once daily, orally.” NCT07240909 ↗ |
| Known as | amlodipine camsylate | “This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with...” NCT01830517 ↗1“amlodipine camsylate 5mg + losartan potassium 100mg treatment (A/L 5/100) group” PMID 29150250 ↗ Nov 2017 |
| Known as | amlodipine orotate | “A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg” NCT01823913 ↗ |
| Known as | Amlodipine Pfizer 10mg (Pfizer) | “Amlodipine Pfizer 10mg (Pfizer)” NCT03106597 ↗ |
| Known as | Amodipin | “This study was conducted to evaluate and compare the effectiveness of Amodipin® (amlodipine camsylate) with that of Cozaar® (losartan potassium) in hypertensive patients with...” NCT01830517 ↗ |
| Known as | Doxazosine | “Doxazosine” NCT00741585 ↗ |
| Known as | HGP0904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02587988 ↗ |
| Known as | Nevibolol | “Nevibolol” NCT00741585 ↗ |
| Known as | Norvasc | “The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks.” NCT01996449 ↗14“Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension” NCT00281580 ↗ “Norvasc®(Amlodipine Besylate) Tablets, 5mg of Pfizer Laboratories Div. Pfizer Inc.” NCT05667818 ↗ “Study drugs: amlodipine (Norvasc®) and nifedipine GITS (Adalat®)” NCT01030081 ↗ “compared with those of amlodipine besilate (Norvasc or Amlodin)” NCT00294567 ↗ “Step 4 - Addition of Norvasc 2.5-10 mg po od.” NCT00438113 ↗ “amlodipine therapy (NORVASC 10 mg/day)” NCT03054467 ↗ “Norvasc (amlodipine) 5mg, 1 tablet/day” NCT05288400 ↗ “Drug: Amlodipine (Norvasc)” NCT01518855 ↗ “Amlodipine 5mg(Norvasc)” NCT04081844 ↗ “amlodipine (Norvasc)” NCT01922687 ↗ |
| Known as | SPC4001 | “The dosages were SPC1001 High (4/2.5/1.25 mg), SPC1001 Mid1 (2.67/1.67/0.83 mg), SPC1001 Mid2 (4/1.25/1.25 mg), SPC1001 Low (2/1.25/0.625 mg), SPC3001 (candesartan 8 mg),...” PMID 41162308 ↗ Oct 2025 |
| Known as | SPC4002 | “The dosages were SPC1001 High (4/2.5/1.25 mg), SPC1001 Mid1 (2.67/1.67/0.83 mg), SPC1001 Mid2 (4/1.25/1.25 mg), SPC1001 Low (2/1.25/0.625 mg), SPC3001 (candesartan 8 mg),...” PMID 41162308 ↗ Oct 2025 |
| Action | Inhibit | “amlodipine, a calcium channel blocker” PMID 24842697 ↗ Jul 2014 |
| Modality | Other / unclassified | “the use of a calcium channel blocker (amlodipine)” NCT04954196 ↗ |
| Route | Oral | “amlodipine po qd” NCT00156403 ↗ |